1 August 2025
Ropes & Gray Advises Matchpoint Therapeutics in Novartis Option and License Agreement Worth Up to $1 Billion
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| David McIntosh Lead | Ropes & Gray | Partner | life sciences licensing | Not stated |
| Ian Nilsen | Ropes & Gray | Associate | life sciences licensing | Not stated |
| David Saltzman | Ropes & Gray | Partner | tax | Not stated |
| Jackie Grise | Ropes & Gray | Partner | litigation & enforcement | Not stated |
| Elizabeth Sun | Ropes & Gray | Associate | tax | Not stated |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1bn ($1 Billion)
- What the figure measures
- Total transaction value
- Client
- Matchpoint TherapeuticsOther
- Counterparties
- Novartis (Other)